Evidence map›Paper›PMID 39364125›Full record

ArticleBioscience of microbiota, food and health2024

Differences in the human gut microbiota with varying depressive symptom severity scores.

Yuka Masamura, Ryuichi Kubo, Yuki Midorikawa, Natsuko O Shinozaki, Satoshi Watanabe, Sayumi Maekawa, Aya K Takeda, Tazro Ohta

Abstract read
In one paragraph

Article in Bioscience of microbiota, food and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuka MasamuraThe Hotchkiss School, 11 Interlaken Rd, Lakeville, CT 06039, USA.
Ryuichi KuboCykinso, Inc., 1-36-1 Yoyogi, Shibuya, Tokyo 151-0053, Japan.
Yuki MidorikawaCykinso, Inc., 1-36-1 Yoyogi, Shibuya, Tokyo 151-0053, Japan.
Natsuko O ShinozakiCykinso, Inc., 1-36-1 Yoyogi, Shibuya, Tokyo 151-0053, Japan.
Satoshi WatanabeCykinso, Inc., 1-36-1 Yoyogi, Shibuya, Tokyo 151-0053, Japan.
Sayumi MaekawaCykinso, Inc., 1-36-1 Yoyogi, Shibuya, Tokyo 151-0053, Japan.
Aya K TakedaCykinso, Inc., 1-36-1 Yoyogi, Shibuya, Tokyo 151-0053, Japan.
Tazro OhtaInstitute for Advanced Academic Research, Chiba University, 1-33 Yayoicho, Inage, Chiba, Chiba 263-8522, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is a prevalent mental health disorder, and its incidence has increased further because of the coronavirus disease 2019 (COVID-19) pandemic. The gut microbiome has been suggested as a potential target for mental health treatment because of the bidirectional communication system between the brain and gastrointestinal tract, known as the gut-brain axis. We aimed to investigate the relationship between the human gut microbiome and depression screening by analyzing the abundance and types of microbiomes among individuals living in Japan, where mental health awareness and support may differ from those in other countries owing to cultural factors. We used a data-driven approach to evaluate the gut microbiome of participants who underwent commercial gut microbiota testing services and completed a questionnaire survey that included a test for scoring depressive tendencies. Our data analysis results indicated that no significant differences in gut microbiome composition were found among the groups based on their depression screening scores. However, the results also indicated the potential existence of a few differentially abundant bacterial taxa. Specifically, the detected bacterial changes in abundance suggest that the Bifidobacteriaceae, Streptococcaceae, and Veillonellaceae families are candidates for differentially abundant bacteria. Our findings should contribute to the growing body of research on the relationship between gut microbiome and mental health, highlighting the potential of microbiome-based interventions for depression treatment. The limitations of this study include the lack of clear medical information on the participants' diagnoses. Future research could benefit from a larger sample size and more detailed clinical information.

Indexed as

16s rRNAdirect-to-consumer Mykinso gut-microbiome testing servicegut microbiotamental health

Identifiers

PMID39364125
PMCPMC11444865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.